NCT06774872View on ClinicalTrials.gov

Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

PHASE2RecruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

June 15, 2028

Conditions
HIV-1-infection
Interventions
DRUG

Doravirine 100Mg Tab and Lamivudine 300 Mg Tab

"Participants randomised in the arm 1 will receive the DORAVIRINE/LAMIVUDINE combination: doravirine (PIFELTRO®) 100 mg 1 pill a day + lamivudine 300 mg 1 pill a day"

DRUG

Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab

"Participants randomised in the arm 2 will receive the DTG/3TC combination: dolutegravir 50 mg/lamivudine 300 mg (DOVATO®) 1 pill a day"

Trial Locations (1)

75013

RECRUITING

Hôpital Pitié-Salpêtrière, Paris

All Listed Sponsors
collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

collaborator

Organization providing support methodology coordination (Institut Pierre Louis d'Epidémiologie et de Santé Publique)

UNKNOWN

lead

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

OTHER